Hill H R, Bathras J M
Rev Infect Dis. 1986 Jul-Aug;8 Suppl 4:S396-400. doi: 10.1093/clinids/8.supplement_4.s396.
The in vitro opsonic activity of a native, pH 4.25 immunoglobulin G preparation modified for intravenous use (IGIV pH 4.25) was compared with the activities of a standard reduced and alkylated, pH 6.8 preparation (IGIV-R/A pH 6.8) and a reduced and alkylated, pH 5.25 preparation (IGIV-R/A pH 5.25) against a variety of common bacterial pathogens. In most instances the opsonic titers of IGIV pH 4.25 equaled or exceeded that of IGIV-R/A pH 6.8; IGIV-R/A pH 5.25 usually had an intermediate level of activity. The protective activity of IGIV pH 4.25 against Escherichia coli in a neonatal rat model was also greater than that of IGIV-R/A pH 6.8. Thus, the functional activity of the new IGIV pH 4.25 apparently equals or exceeds that of standard reduced and alkylated preparations.
将一种经改良可用于静脉注射的天然pH 4.25免疫球蛋白G制剂(pH 4.25静脉注射用免疫球蛋白)的体外调理活性,与一种标准的经还原和烷基化处理的pH 6.8制剂(pH 6.8还原烷基化静脉注射用免疫球蛋白)以及一种经还原和烷基化处理的pH 5.25制剂(pH 5.25还原烷基化静脉注射用免疫球蛋白)针对多种常见细菌病原体的活性进行了比较。在大多数情况下,pH 4.25静脉注射用免疫球蛋白的调理滴度等于或超过pH 6.8还原烷基化静脉注射用免疫球蛋白;pH 5.25还原烷基化静脉注射用免疫球蛋白的活性通常处于中等水平。在新生大鼠模型中,pH 4.25静脉注射用免疫球蛋白对大肠杆菌的保护活性也高于pH 6.8还原烷基化静脉注射用免疫球蛋白。因此,新的pH 4.25静脉注射用免疫球蛋白的功能活性显然等于或超过标准的经还原和烷基化处理的制剂。